Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Can J Kidney Health Dis ; 10: 20543581231156853, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37051047

RESUMO

Background: The illicit drug toxicity (overdose) crisis has worsened across Canada, between 2016 and 2021 more than 28 000 individuals have died of drug toxicity. Organ donation from persons who experience drug toxicity death has increased in recent years. Objective: This study examines whether graft loss after kidney transplantation differed by donor cause of death. Design: Retrospective cohort. Setting: Provincial transplant program of British Columbia, Canada. Patients: Transplant recipients who received kidney transplantation from deceased donors aged 12 to 70 years between 2013 and 2019 (N = 1012). Measurements: Transplant recipient all cause graft loss (graft loss due to any cause including death) was compared by donor cause of death from drug toxicity or other. Methods: Five-year Kaplan-Meier estimates of all-cause graft survival, and 3-year complete as well as stratified inverse probability of treatment weighted Cox proportional hazards models were conducted. Results: Drug toxicity death donors donated to 25% (252/1012) of kidney transplantations. Drug toxicity death donors were more likely to be young, white, males, with fewer comorbidities such as diabetes or hypertension but were more likely to have a terminal serum creatinine ≥1.5 mg/dL or be hepatitis C virus (HCV) positive. Unadjusted 5-year estimate of all-cause graft survival was 97% for recipients of drug toxicity donor kidneys and 83% for recipients of non-drug toxicity donor kidneys (P < .001). Recipients of drug toxicity death donor kidneys had decreased risk of all cause graft loss compared to recipients of non-drug toxicity death donor kidneys (hazard ratio [HR]: 0.30, 95% confidence interval [CI]: 0.12-0.77, P = .012). This is primarily due to the reduced risk of all-cause graft loss for recipients of younger (≤35 years) drug toxicity death donor kidneys (HR: 0.05, 95% CI: 0.00-0.55, P = .015). Limitations: Potential selection bias, potential unmeasured confounding. Conclusions: Donation after drug toxicity death is safe and should be considered more broadly to increase deceased donor kidney donation.


Contexte: La crise liée à la toxicité des drogues illicites (surdose) s'est aggravée partout au Canada. Entre 2016 et 2021, plus de 28 000 personnes sont mortes en raison de la toxicité des drogues. Les dons d'organes provenant de personnes décédées d'une surdose ont augmenté dans les dernières années. Objectif: Déterminer si la cause de décès du donneur influe sur la survie du greffon après une transplantation rénale. Conception: Étude de cohorte rétrospective. Cadre: Program provincial de transplantation de la Colombie-Britannique (Canada). Sujets: Des receveurs (N=1012) d'une greffe de rein entre 2013 et 2019 dont l'organe provenait de donneurs décédés âgés de 12 à 70 ans. Mesures: La perte du greffon toutes causes confondues (y compris le décès du receveur) a été comparée selon la cause de décès du donneur, que celle-ci soit attribuable à une surdose ou à une autre cause. Méthodologie: Des estimations de Kaplan-Meier de la survie de la greffe toutes causes confondues à 5 ans et à 3 ans ont été réalisées, ainsi que des modèles de risques proportionnels de Cox à probabilité inverse de traitements pondérés. Résultats: Les donneurs décédés par surdose comptaient pour 25 % (252/1012) des organes reçus pour les transplantations rénales. Les donneurs dont le décès était attribuable à une surdose étaient plus susceptibles d'être de jeunes hommes blancs présentant moins de comorbidités comme le diabète ou l'hypertension, mais plus susceptibles d'avoir un taux de créatinine sérique terminal d'au moins 1,5 mg/dl ou d'être positifs pour l'hépatite C. L'estimation non corrigée de la survie du greffon toutes causes confondues après 5 ans était de 97 % pour les reins provenant de donneurs décédés d'une surdose et de 83 % pour les reins provenant de donneurs décédés d'une autre cause (p < 0,001). Les receveurs d'un rein provenant d'un donneur décédé par surdose présentaient un plus faible risque de perte du greffon toutes causes confondues comparativement aux receveurs d'un rein de donneur décédé d'une autre cause (risque relatif [RR]: 0,30; intervalle de confiance à 95 % [IC 95 %]: 0,12-0,77; p=0,012). Ces résultats sont principalement attribuables à un plus faible risque de perte du greffon toutes causes confondues lorsque le rein provient d'un donneur plus jeune (≤ 35 ans) même si ce dernier est décédé de surdose (RR: 0,05; IC 95 %: 0,00-0,55; p=0,015). Limites: Possible biais de sélection; possibles facteurs de confusion non mesurés. Conclusion: Le don d'organes à la suite d'un décès par surdose est sans danger et devrait être envisagé plus largement afin d'augmenter les dons de reins par des donneurs décédés.

2.
Clin Transplant ; 37(3): e14866, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36512481

RESUMO

INTRODUCTION: The illicit drug toxicity (overdose) crisis has worsened across Canada; between 2016 and 2021, more than 28,000 individuals have died of drug toxicity. Organ donation from persons who experience drug toxicity death (DTD) has increased in recent years. This study examines whether survival after heart or bilateral-lung transplantation differed by donor cause of death. METHODS: We studied transplant recipients in British Columbia who received heart (N = 110) or bilateral-lung (N = 223) transplantation from deceased donors aged 12-70 years between 2013 and 2019. Transplant recipient survival was compared by donor cause of death from drug toxicity or other. Five-year Kaplan-Meier estimates of survival and 3-year inverse probability treatment weighted Cox proportional hazards models were conducted. RESULTS: DTD donors made up 36% (40/110) of heart and 24% (54/223) of bilateral-lung transplantations. DTD donors were more likely to be young, white, and male. Unadjusted 5-year recipient survival was similar by donor cause of death (heart: 87% for DTD and 86% for non-DTD, p = .75; bilateral- lung: 80% for DTD and 76% for non-DTD, p = .65). Adjusted risk of mortality at 3-years post-transplant was similar between recipients of DTD and non-DTD donor heart (hazard ratio [HR]: .94, 95% confidence interval (CI): .22-4.07, p = .938) and bilateral-lung (HR: 1.06, 95% CI: .41-2.70, p = .908). CONCLUSION: Recipient survival after heart or bilateral-lung transplantation from DTD donors and non-DTD donors was similar. Donation from DTD donors is safe and should be considered more broadly to increase organ donation.


Assuntos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Transplante de Coração , Transplante de Pulmão , Obtenção de Tecidos e Órgãos , Humanos , Masculino , Doadores de Tecidos , Colúmbia Britânica , Estudos Retrospectivos , Sobrevivência de Enxerto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...